ADVERTISEMENT
Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL
06/29/2020
Arnon P. Kater, MD, PhD, Professor of Hematology, Amsterdam University Medical Center, the Netherlands, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax monotherapy in patients with relapsed/refractory CLL. These results were presented at the virtual 2020 EHA Annual Congress.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement